<DOC>
	<DOCNO>NCT01253382</DOCNO>
	<brief_summary>The primary objective study : - ass safety tolerability ecallantide paediatric patient acute attack HAE The secondary objective : - evaluate pharmacokinetic profile ecallantide paediatric patient treat acute attack HAE - ass efficacy ecallantide paediatric patient treat moderate severe acute attack HAE</brief_summary>
	<brief_title>Study Evaluate Ecallantide Paediatric Patients With Acute Attacks Hereditary Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>1 . Male female 2 year age prepubertal 2 . Physician diagnosis history HAE ( Type I II ) include laboratory result show C11NH activity lower limit normal 15 % low limit normal range 3 . Present site moderate severe sign symptom acute attack HAE within 8 hour recognition onset attack . Spontaneous resolution attack must begin administration study drug . 4 . Must sign informed consent parent caregiver . 1 . &lt; 2 year age reach puberty 2 . Received treatment ecallantide within previous 72 hour 3 . Received investigational drug device , ecallantide , within 30 day prior screen visit 4 . Pharyngeal/laryngeal symptoms 5 . Mild attack include mild edema extremity mild abdominal attack 6 . Are unable unwilling give inform consent ( parent caregiver ) 7 . Any condition , opinion investigator , may compromise safety compliance patient would preclude patient successful completion study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>